कंपनी का अवलोकन
NRx Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical entity dedicated to the development of novel therapeutics designed to address central nervous system disorders, specifically targeting conditions such as suicidal depression, post-traumatic stress disorder, and chronic pain. The company operates within the Healthcare sector and functions specifically in the Biotechnology industry, which distinguishes its business model from mature pharmaceutical firms by focusing on early-stage research and development rather than established product sales. In terms of scale, NRx Pharmaceuticals holds a market capitalization of $73.74 million, reports a trailing twelve-month revenue of $1.23 million, and employs a workforce of 29 individuals. These financial figures indicate that the company operates with a relatively small market cap and limited annual revenue generation, characteristic of early-stage biotechnology firms that prioritize capitalizing on research pipelines over immediate commercial profitability. The low revenue figure relative to the market cap suggests that the company's valuation is heavily dependent on the potential future success of its lead drug candidates, such as NRX-101, rather than current cash flows from existing products.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $1.23 million alongside a net income of $-28,622,000 and an EBITDA of $-16,118,000, highlighting a significant gap between revenue and profitability that reveals a cost structure dominated by high research and development expenses. This substantial disparity between the modest revenue of $1.23 million and the net loss of $28.62 million demonstrates that the company is currently burning cash to advance its clinical pipeline rather than generating profit from sales. Free cash flow stands at $-805,875, indicating that the company is consuming cash reserves to fund operations and development activities, which limits its financial flexibility without continuous external financing. The gross margin is recorded at 58.8%, while the operating margin is -467.3% and the profit margin is 0.0%, illustrating that while the cost of goods sold is manageable relative to revenue, operational expenses are so high that they severely erode profitability before interest and taxes. Total cash on hand is $7.80 million compared to total debt of $631,000, and the debt-to-equity ratio is listed as N/A, suggesting a capital structure that relies primarily on equity or intangible assets rather than traditional leverage. Despite the low debt load, the current ratio of 0.31 indicates a liquidity position where current liabilities exceed current assets, signaling potential short-term liquidity constraints that the company must manage carefully. Furthermore, the return on equity is N/A and the return on assets is -121.8%, which reveals that management is currently unable to generate positive returns on the capital invested in the business due to the heavy losses associated with the clinical-stage nature of the operations.
मूल्यांकन आकलन
The valuation metrics show a trailing P/E ratio of N/A and a forward P/E of 17.15, implying that while the company has not yet generated consistent earnings to support a trailing multiple, analysts project a return to profitability that would result in a forward P/E valuation. The price-to-book ratio is -4.43, a negative figure that indicates the market values the company's equity significantly below its book value, often reflecting the challenges of valuing intangible assets and the risk profile of a biotechnology firm with no current earnings. Additionally, the price-to-sales ratio is 60.20 and the EV/EBITDA is -4.13, suggesting that investors are willing to pay a premium multiple of sales given the high revenue-to-price relationship, even though the negative EV/EBITDA reflects the company's current lack of earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $3.84 and a 52-week low of $1.62, and based on the provided data, the current price context relative to this range must be inferred from the forward P/E of 17.15 which implies a specific price point within this historical band. The beta value is 1.83, indicating that the stock's price volatility is significantly higher than that of the broader market, as a beta greater than 1.0 suggests that NRXP tends to amplify market movements with greater intensity. This high volatility is typical for small-cap biotechnology stocks where stock prices can swing dramatically based on clinical trial results or regulatory announcements, making the price highly sensitive to sector-wide sentiment.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data available to compare current performance against the previous year, which prevents a direct analysis of whether earnings are growing faster or slower than revenue. Because the company has not yet achieved profitability, the payout ratio is 0.0% and the dividend yield is N/A, confirming that NRx Pharmaceuticals does not distribute dividends to shareholders. Instead of paying out income, the company reinvests all available earnings and cash reserves into its research and development efforts to advance its clinical-stage drug candidates toward market approval. This lack of dividend income combined with N/A growth rates defines a pure growth profile where investors seek potential capital appreciation from future product launches rather than current cash distributions or consistent earnings expansion. The overall growth and income profile is characterized by an absence of current profitability and dividend payments, relying entirely on the successful commercialization of future therapeutics to generate returns for shareholders.